In this era of SGLT2 inhibitors and GLP1 agonists, we need to initiate these therapies early because of their cardioprotective and renoprotective (for SGLT2I) benefits

The incidence of heart failure, silent ischaemia and arrhythmias are higher in patients with T2DM and GPs need a high index of suspicion to identify, diagnose and treat these

 

Host: Dr David Lim | Total time: 27 mins

Guest: A/Prof Neale Cohen, Endocrinologist; Director of Clinical Diabetes, the Baker Heart and Diabetes Institute, Melbourne

Register for our fortnightly FREE WEBCASTS

Every second Tuesday | 7:00pm-9:00pm AEST

Click here to register for the next one

See omnystudio.com/listener for privacy information.